Efficacy of group cognitive-behavioral therapy in adolescents with obsessive compulsive disorder: a systematic review and meta-analysis

Cristiane F. Bortoncello,1 Nicolas de Oliveira Cardoso,2 Eduarda Z. Salvador,2 Richard C. de Avila,3 Wagner de L. Machado,2 Ygor A. Ferrão3

1Departamento de Clínica Médica (neurociências), Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil. 2Grupo de Pesquisa Avaliação em Bem-estar e Saúde Mental (ABES), Departamento de Psicologia, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil. 3Departamento de Clínica Médica (neurociências), UFCSPA, Porto Alegre, RS, Brazil.

Objective: To evaluate the effectiveness of group cognitive-behavioral therapy (GCBT) for the treatment of adolescents with obsessive compulsive disorder (OCD).

Methods: This review was registered in PROSPERO under number CRD42020158475. Five databases (PubMed, Virtual Health Library, Web of Science, Scopus, and PsycINFO) were searched. After applying the inclusion and exclusion criteria, 13 studies were analyzed in the qualitative synthesis (i.e., systematic review) and eight in the quantitative synthesis (i.e., meta-analysis). For the latter, fixed-effect modeling was used to assess the primary outcome (i.e., OCD symptoms). The main findings suggest that GCBT is effective in reducing the symptoms of OCD in adolescents (d = -1.32). However, these results must be interpreted with caution, since all of the included studies showed some bias in their design.

Conclusions: GCBT is effective in reducing OCD symptoms in adolescents.

Keywords: Group cognitive-behavioral therapy; obsessive compulsive disorder; adolescents

Introduction

Obsessive compulsive disorder (OCD) is a serious mental illness, uncommon in young children (between 2-3 years old) and very common in adolescence,1 and is among the ten diseases that most cause disability.2 In Brazil, a study with 842 clinical patients found an average age at symptom onset of 12.4 years in men and 12.7 years in women,3 with similar findings reported in the international literature,4,5 and a prevalence of approximately 2 to 3% among children and adolescents.4,6,7

Considered multifactorial, with both genetic and environmental aspects involved in its pathogenesis,8-10 OCD is four times more likely to develop in first-degree relatives of persons with the disorder.11,12 In addition, as the course is chronic, it is usually lifelong if untreated, rarely remitting completely.1 Establishing diagnosis and treatment as early as possible is important to prevent worsening of symptoms and increase the odds of complete remission.13-15 A study with adolescents in southern Brazil found that only 9.3% of those diagnosed with OCD were aware of their diagnosis, and, of these, only 6.7% had undergone some type of treatment.7 Since OCD is not always perceived by the family, there is often a long interval between the onset of symptoms and the search for treatment,16-18 which can be a predictor of poor prognosis.19

In children and adolescents with OCD, both cognitive-behavioral therapy (CBT) and psychoactive drugs are effective in reducing obsessive-compulsive symptoms (OCS).20,21 Treatment with CBT is superior to isolated pharmacotherapy.22,23 The efficacy and effectiveness of CBT for OCD in this age group has been verified through clinical trials, systematic reviews, and meta-analyses.20,22,24 Therefore, CBT is considered the first-line treatment of choice in children and adolescents with mild and moderate symptoms of OCD (e.g., predominance of compulsions, absence of comorbidities).20,25,26 As a second-line choice, CBT combined with pharmacotherapy is recommended in cases of moderate to severe symptom intensity or when there is comorbid depression.26,27

Although the literature shows a reduction in symptoms after treatment, in practice there are some difficulties: 20 to 32% of children with OCD do not respond (or respond only partially) to individual CBT (ICBT), with or without concomitant medication.15,20,25 Therefore, some researchers...
recommend the use of group CBT (GCBT) for the treatment of children and adolescents with OCD, since there is evidence of a significant reduction in symptoms in adults undergoing this treatment modality. In addition, evidence suggests that GCBT is more effective in treating OCD in adults than the use of fluoxetine. Furthermore, it is highlighted that GCBT can treat a greater number of patients at the same time, thus making psychotherapy more accessible for the population.

Unfortunately, there are few studies evaluating the effectiveness of GCBT in children and adolescents with OCD. Finally, considering that OCD symptoms usually start between 10 and 12 years of age and that, as far as we are aware, there are no systematic reviews with or without meta-analysis exclusively evaluating the effects of GCBT in adolescents with OCD, this study aims to evaluate the effectiveness of GCBT for the treatment of adolescents with OCD.

Method

A systematic review with meta-analysis was performed following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and according to pre-established steps defined in the study protocol, as registered in PROSPERO (CRD42020158475). Data collection occurred through online searches of five databases: Virtual Health Library (BVS), Web of Science, Scopus, American Psychological Association database (PsycINFO), and PubMed (via MEDLINE).

To identify scientific studies related to the objective of this review, the following key descriptors were used: (“behavioral therapies” or “behavioral therapy” or “cognitive behavioral therapy” or “cognitive behavioral therapies”) and (adolescent * or adolescence or teen * or teenager * or youth *) and (obsessive compulsive disorder or obsessive-compulsive disorders or obsessive behavior or obsessive behaviors) and (group psychotherapy or group therapy). All descriptors were drawn from the Medical Subject Headings (MeSH/PubMed) and TheSaurus (PsycINFO) controlled vocabularies.

The searches were performed by two independent evaluators in April 2021. Although the same key descriptors were used in all databases, search strategies were customized for each database. For BVS, PubMed, Web of Science, and PsycINFO, all descriptors were used in a single line. This required the advanced search tab in BVS to ensure coverage of the titles and summary of articles. For Scopus, due to the inability of the database to group all descriptors on a single line, the query was divided into four lines: first line: (“behavioral therapies” or “behavioral therapy” or “cognitive behavior therapy” or “cognitive behavioral therapies”); second line: (adolescent * or adolescence or teen * or teenager * or youth *); third line: (obsessive compulsive disorder or obsessive-compulsive disorders or obsessive behavior or obsessive behaviors); fourth line: (group psychotherapy or group therapy). The filter “article” was used in Scopus, BVS, and Web of Science, while in PsycINFO, the filter “journal” was used. No filters were used in PubMed.

The total yield of the search of databases was imported into Rayyan, an online tool developed to help authors of systematic reviews and meta-analyses store their results in a single online database and produce articles with higher quality and methodological rigor. This online platform has a blind review mode, which allows two or more reviewers to individually select articles. Reviewers can add comments to each article and group them into three categories: 1) included, 2) excluded, or 3) perhaps. In addition, Rayyan automatically identifies all duplicate articles and allows the blind review mode to be removed, automatically revealing a fourth category of articles called “conflicts,” which contains all the articles on which the reviewers had divergent opinions. After excluding duplicate articles, the evaluators read the titles and abstracts of the remaining studies based on the following inclusion and exclusion criteria.

Eligibility criteria (PICOS)

Participants (P)

A study was eligible if its sample met the following criteria: 1) adolescents (age between 10 and 19 years) of any gender; 2) established diagnosis of OCD (any stage of illness) using any standard diagnostic criteria (e.g., DSM-5 or ICD-10).

A study was ineligible if its sample met the following criteria: 1) heterogeneous sample in the same intervention group (i.e., children and adolescents or adolescents and young adults), with group mean age under 10 or over 19; 2) sample composed exclusively of children (under 10); 3) sample composed exclusively of adults (over 19).

Interventions and comparators (I and C)

A study was eligible if its intervention and comparators met one of the following criteria: 1) at least one group in GCBT condition (alone or in combination with medication); 2) comparison of GCBT with itself (pre/post-test); 3) comparison of GCBT with ICBT or another form of individual or group psychotherapy (both online and face-to-face); 4) comparison of GCBT with medication use; 5) comparison of GCBT with any other forms of treatment (e.g., no treatment/waiting list/treatment as usual). A study was ineligible if it used only behavioral or only cognitive therapy.

Outcomes (O)

A study was eligible if its outcomes met the following criteria: 1) changes in OCD symptoms measured by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) or Children’s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS), which is an adaptation of the Y-BOCS developed specifically for the assessment of children and adolescents, being the gold standard for measuring OCD symptoms in this age group; 2) measurement of OCD symptoms on at least two time points (e.g., baseline and end of treatment).
Study design (S)

A study was eligible if its design met the following criteria: 1) randomized controlled trial or single group pre-post trial or any experimental and quasi-experimental design, regardless of the level of blinding (qualitative synthesis); 2) provides sufficient statistics to be included in the meta-analysis (quantitative synthesis). The year of publication and language of the papers were not restricted, aiming to find as many articles as possible. These criteria were first applied by two independent researchers during the screening of titles and abstracts in Rayyan. In the second stage, the remaining papers were read in full. The included papers were assessed for risk of bias using two tools: 1) Cochrane Collaboration risk of bias tool (RoB), which covers selection, performance, detection, attrition, reporting, and other bias for RCTs; and 2) the Cochrane risk of bias tool to assess non-randomized studies of interventions (ROBINS-I), which covers confounding, selection, classification, deviation, missing data, and reporting bias, for non-RCTs. Any inconsistencies between the two independent researchers were resolved by a third senior author. After these steps were completed, a manual reference search was conducted on all included full-text articles.

Data extraction

After selecting the articles, the extraction of all data was performed by two independent evaluators. To address the objectives of this systematic review, the following data were extracted from the included articles: 1) study identification (authors last name, design, year of study or publication); 2) country; 3) diagnosis (i.e., OCD and comorbidities); 4) sample size; 5) sample age (mean); 6) gender distribution; 7) study population; 8) OCD assessment measures; 9) main findings; 10) mean, standard deviation, or percentage in all groups at pre-test and post-test; 11) type and duration of interventions; 12) time point(s) of outcome measurement; 13) previous experience with psychotherapy; 14) risk of bias. Studies that did not present enough data to perform meta-analysis (e.g., number of participants in each group after drop-out, mean scores in the pre- and post-test, standard deviation [SD]) were excluded from the quantitative synthesis (i.e., meta-analysis), but were retained for the qualitative synthesis (i.e., systematic review).

Data synthesis

Meta-analyses were performed to evaluate the effectiveness of GCBT and other interventions in adolescents with OCD. The post-treatment effects and different control conditions or comparison to other interventions were evaluated. The meta-analyses were performed in R software 3.6, using the “meta” package, which allows estimation of fixed and random effects and the assessment of heterogeneity. An I² statistic of ≥ 75% was deemed to indicate substantial levels of between-study heterogeneity. The effects of GCBT were presented as standardized effect sizes (Cohen’s d). An effect size ≥ 0.8 is considered a large clinical effect; an effect size ≥ 0.5, moderate; and ≥ 0.2, small.

Results

Initially, 713 articles were found, with 13 studies remaining after application of the pre-established inclusion and exclusion criteria. A hand search of the references of these studies yielded no additional publications. Figure 1 shows a PRISMA flow diagram of data selection. Table 1 lists the main characteristics of the studies and interventions. Table 2 lists the main characteristics of the participants.

Most of the included studies were conducted in Australia (n=5; 38.5%) and in the United States (n=4; 30.8%). Only two studies (15.3%) were performed in Brazil, one (7.7%) in Canada, and one (7.7%) in Iran. Of the 13 studies, six (46.1%) were RCTs and seven (53.9%) were non-randomized (i.e., quasi-experimental). Only three (23.1%) studies performed follow-up, and each used a different time to assess the effect after treatment (12, 18, and 84 months). Among the seven protocols used by the included studies, only two were followed by more than one of the studies. The most used protocol was “How I ran OCD off My Land” (n=4; 39.8%), which was tested on Brazilian samples. Furthermore, only two (15.4%) of the 13 included studies used the Y-BOCS measure OCD symptoms in adolescents. The other 11 (84.6%) studies used CY-BOCS.

Regarding the interventions and comparisons used, most protocols (n=7; 53.8%) used only pre- and post-test comparisons to identify the effectiveness of GCBT in adolescents with OCD. The Australian RCTs all followed a similar methodology, with three groups: waiting list, individual cognitive-behavioral family therapy (ICBF), and group cognitive-behavioral family therapy (GCBFT). Two other RCTs compared the use of medication (SSRI) with GCBT. Finally, the Iranian RCT compared individuals in three groups: acceptance and commitment therapy (ACT) + selective serotonin reuptake inhibitors (SSRI); GCBF + SSRI; and SSRI only.

The treatment lasted 7 to 14 weeks, with an average duration of ± 12.3 weeks. Sessions occurred once a week in all included studies. The duration of each session ranged from 60 to 120 minutes (average, 90 minutes). In addition, there was parental participation in all sessions of all included studies, except for study three, where parents could choose to participate in an extra weekly session. However, the time of participation and level of parental involvement in each study varied considerably: the briefest intervention with parents lasted 15 minutes at the end of the sessions, while the longest had a group dedicated exclusively to parents with a duration of 60 minutes.

The sample size of the included studies ranged from 15 to 85 participants. The sum of samples from all studies was 549, with an average of 45.75 (SD = 27.62) participants. The distribution by sex was matched in all studies, resulting in a total of 290 male (52.9%) and 259 female (47.1%) participants.
258 female (47.1%) subjects. Anxiety disorders were the most prevalent comorbidities. However, four articles did not report whether the participants had any comorbidities. Part of the samples from all included studies used some medication before or during GCBT interventions, with SSRIs being the most often used class of drugs. Although most studies (n = 8; 61.5%) reported which drugs were used, only RCTs controlled for the effect of these medications. In addition, most studies (n = 7; 38.5%) did not report how long the participants had been on medication. Among those studies that reported this variable (n = 4; 30.8%), participants remained on the same medication and dosage for 3 weeks to 3 months before the start of the GCBT intervention.

**Meta-analysis**

To perform the meta-analysis of the effect sizes of GCBT interventions, only the pre- and post-test measures of the studies included in the qualitative synthesis stage were considered. Follow-up measures were not evaluated due to incompatibility of time periods and regression toward the mean.\(^56,57\) In addition, two of the studies (8 and 11) did not provide sufficient data (i.e., mean and standard deviation of the groups) for inclusion in the meta-analysis. Therefore, quantitative analyses were performed with eight of the 13 studies included in the qualitative synthesis (Figure 2).

All eight studies reported data on OCD symptom scores using the same psychometric instrument (i.e., Y-BOCS or CY-BOCS) and intervention (i.e., GCBT). A fixed-effect meta-analysis was estimated using mean, standard deviation, and sample size for each study and standard mean difference (SMD) as a measure of effect size. The main findings indicated an overall significant difference ($d = -1.32$) between pre-test and post-test scores in favor of GCBT. There was a slight difference between experimental and quasi-experimental designs. The effect observed in the experimental studies was greater ($d = -2.07$) compared to the quasi-experimental design.
| Reference and country | Study design | Protocol used | Intervention (comparison) | Duration of treatment | Weekly sessions (duration) | Family participation (how many/which sessions) | Outcome measures |
|-----------------------|--------------|---------------|---------------------------|-----------------------|---------------------------|-----------------------------------------------|-----------------|
| Fischer,28 United States | NRCT         | A standardized behavioral group treatment program for obsessive-compulsive disorder45 | GCBT (pre/post-test) | 7 weeks                | 1 (1.5h)                        | 7 educational sessions (optional) open to everyone (family and clients) | CY-BOCS         |
| Thienemann,29 United States | NRCT         | OCD in Children and Adolescent: A Cognitive-Behavioral Treatment Manual46 - How I ran OCD off My Land | GCBT (pre/post-test) | 14 weeks              | 1 (2h)                          | Last 15 min of each session + 1 session with the participation of parents and siblings | CY-BOCS         |
| Himle,47 United States | NRCT         | Group behavioral therapy for adolescents with obsessive-compulsive disorder18 | GCBT (pre/post-test) | 7 weeks                | 1 (1.5h)                        | 1 optional weekly session with patients and family | CY-BOCS         |
| Barrett,30 Australia | RCT          | Freedom From Obsessions and Compulsions Using Cognitive-Behavioral Strategies (FOCUS) | GCBFT (ICBFT and waitlist) | 14 weeks + 2 booster sessions after 1 month and after 3 months of the intervention | 1 (1.5h)                        | 50 min children 10 min parents + children 30 min parents (skills training) | CY-BOCS         |
| Barrett,13 Australia |              | 12 and 18 months follow-up |                           |                        |                           |                                               |                 |
| O'Leary,14 Australia |              | 7-year follow-up |                           |                        |                           |                                               |                 |
| Martin,49 United States | NRCT         | How I ran OCD off My Land46 | GCBT (pre/post-test) | 14 weeks              | 1 (1.5h)                        | Two simultaneous groups: 60 min children (G1)/60 min parents (G2) At the end of each session, the groups got together for 30 min | CY-BOCS         |
| Asbahr,22 Brazil | RCT          | How I ran OCD off My Land46 | GCBT (sertraline) | 12 weeks              | 1 (1.5h)                        | Last 15 min of each session + 1 session with the participation of parents and siblings | CY-BOCS         |
| Farrell,50 Australia | NRCT         | OCD Busters (Child and Adolescent Versions) | GCBT (pre/post-test) | 13 weeks + 2 booster sessions after 1 month and after 3 months of the intervention | 1 (1.5h)                        | Last 15 min of each session + 3 group sessions with parents (1 h) and two individual sessions with each family (1 h) | CY-BOCS         |
| Lavell,51 Australia |              | 12 months follow-up |                           |                        |                           |                                               |                 |

Continued on next page
| Study design | Intervention (comparison) | Duration of treatment | Weekly sessions (duration) | Family participation (how many/which sessions) | Outcome measures |
|--------------|--------------------------|-----------------------|-----------------------------|-----------------------------------------------|------------------|
| RCT          | How I ran OCD off My Land > with language adaptation for Brazil through the Cordioli protocol | 14 weeks | 1 (1.7h) | Parents of the FLX group were invited to accompany their children during biweekly consultations with the doctor. Last 15 min of each session + 1 session with the participation of parents and siblings | Y-BOCS |
| NRCT         | OCD is Not the Boss of Me | 12 weeks | 1 (1.5h) | Parents participated in a Parent Group and in the final 15-30 min of each session they join their children to answer questions and receive the homework | CY-BOCS |
| RCT          | How I ran OCD off My Land [46] | 12 weeks | 1 (1h) | Last 5 min of each session, they received a summary of what was discussed and were instructed not to reinforce obsessive behaviors | CY-BOCS |

ACT = acceptance and commitment therapy; CY-BOCS = Children's Yale-Brown Obsessive Compulsive Scale; FLX = fluoxetine; GCBT = group cognitive-behavioral therapy; GCBFT = group cognitive-behavioral family therapy; GFCBT = group family-based cognitive behavioral therapy; ICBFT = individual cognitive-behavioral family therapy; NR = not reported; NRCT = non-randomized clinical trial; OCD = obsessive compulsive disorder; RCT = randomized clinical trial; SSRI = selective serotonin reuptake inhibitors; Y-BOCS = Yale-Brown Obsessive Compulsive Scale.
Table 2 Characteristics of the participants

| Study     | Sample size | Mean age (SD) | Sex ratio | Psychiatric comorbidities                                                                 | SMP | Medication                      | Time of use  |
|-----------|-------------|---------------|-----------|------------------------------------------------------------------------------------------|-----|---------------------------------|--------------|
| Fischer²⁸ | 15          | 14.5 (NR)     | 9M; 6F    | NR                                                                                       | 67% | SSRI                            | 3 weeks BI   |
| Thienemann²⁹ | 18        | 15.2 (NR)     | 12M; 6F   | SOPH (n=3); MD (n=3); ED (n=1); SPPH (n=1); TD (n=1); TS (n=1); ID (n=1)                | 83% | NR                              | NR           |
| Himle⁴⁷   | 19          | 14.63 (1.71)  | 11M; 8F   | MD (n=7); DYS (n=1); ADHD (n=4); ODD (n=2); SAD (n=4); PD (n=1); SOPH (n=1); AG (n=2); SPPH (n=2); GAD (n=1) | 68% | SSRI                            | 3 weeks BI   |
| Barrett³⁰ | 77          | ICBFT – 10.75 (2.54) | ICBFT (12M;12F) | GAD (n=46); SPPH (n=27); SOPH (n=15); SAD (n=13); DYS (n=4); MD (n=2) | ICBFT (12.5%) | NR                              | 3 months BI  |
|           |             | GCBFT – 12.90 (2.30) | GCBFT (13M;16F) |等候组 (13M;11F) | GCBFT (20.7%) | NR                              | NR           |
| Barrett¹³ | 48          | ICBFT – 12.91 (2.57) | ICBFT (11M;11F) | GCBFT (12M;14F) | ICBFT (9%) | GCBFT (15%) | NR | NR |
| O'Leary¹⁴ | 38          | ICBFT – 17.6 (2.75) | ICBFT (9M;10F) | GCBFT – 19.2 (2.81) | GCBFT (11M;8F) | NR | 34% | SSRI | NR |
| Martin⁴⁹  | 14          | 11.3 (NR)     | 4M; 9F    | ADHD (n=5); PDD or NVLD (n=4); TTM (n=2); SPPH (n=2); GAD (n=1); TD (n=1); SOPH (n=1) | 64% | SSRI                            | NR           |
| Asbahr²²  | 40          | GCBT – 13.7 (2.32) | GCBT (15M; 5F) | MD (n=7); mania (n=1); anxiety disorders (n=12); ODD (n=6); TD (n=21); enuresis (n=4); ADHD (n=9); ED (n=1) | Only group | Sertraline | SSRI | - |
| Farrell⁵⁰ | 43          | 11.09(2.52)   | 30M 13F   | GAD (n=14); SAD (n=4); SOPH (n=8); SPPH (n=11); MD (n=3); DYS (n=2); ADHD (n=8); ODD (n=1); PDD (n=15) | 67% | SSRI                            | NR           |
| Lavell⁵¹  | 83          | GCBT – 11.4 (3.2) | GCBT (22M; 18F) | MD (n=16); anxiety disorders (n=65); disruptive disorders (n=23); TD (n=17) | Only group | FLX | SSRI | - |

FLX – 12.1 (3.1) | FLX (18M; 25F) |
studies \((d = -1.15)\), probably due to greater control for intervening variables. In addition, the study intervention conducted by Shabani et al.\(^\text{55}\) which consisted of a combination of GCBT and SSRI, had an effect similar to that of a GCBT-only intervention in the study by Barrett et al.\(^\text{30}\).

As for quasi-experimental studies, those of Selles et al.\(^\text{54}\) and Farrell et al.\(^\text{50}\) represent 52.1% of the weight of this meta-analysis. This may be associated with their considerably greater number of participants. Finally, there is a significant level of heterogeneity in the overall model \((I^2 = 60\%)\), which may be related to participants’ comorbidities, previous experience with individual CBT, and/or medication use.

**Risk of bias in included studies**

A summary of the possible biases in the selected studies (evaluated with ROBINS-I for NRCTs,\(^\text{41}\) and with RoB for RCTs\(^\text{46}\)) is presented in Table 3. All studies showed a high risk of bias in at least one of the topics analyzed. All NRCTs were classified as having a high risk of confounding bias due to sample medication use, multiple comorbidities, or previous treatment with CBT. One study was classified as high risk of selection bias due to selection of participants for the intervention based on the clinical perception that these individuals would benefit from the treatment modality. Three studies were classified as unclear risk of measurement bias due to the lack of information regarding use of the CY-BOCS/Y-BOCS by raters who were not involved in providing group treatment. All studies were classified as unclear risk of reporting bias due to non-presentation of the registration number of the clinical trial and/or non-publication of the study protocol. None of the studies were classified as having a high risk of classification or deviation bias.

All RCTs were classified as having a low risk of selection, performance, detection, and attrition bias. Half of the RCTs \((n=2)\) were classified as unclear risk of reporting bias due to non-presentation of the registration number of the clinical trial and/or non-publication of the protocol. Other sources of bias involved the assessment of bias from previous experience with CBT. This bias was classified as high risk in one RCT since at least one-third of the samples had already undergone CBT in the past. In addition, although five NRCTs also included participants with previous experience with CBT, only one of these trials (study 3) reported how long the participants underwent prior treatment. Thus, at least four NRCTs (studies 1, 2, 7, 12) and one RCT (study 11) may not have controlled for possible effects related to previous experience with psychotherapy.

**Discussion**

This systematic review with meta-analysis aimed to assess the effectiveness of GCBT in adolescents with OCD. After an extensive review of the scientific literature, 13 studies (RCTs or NRCTs) were identified, which used seven different intervention protocols. The main results suggest that GCBT for adolescents is effective in...
reducing the symptoms of OCD, with a reduction of approximately one standard deviation in symptoms between pre-intervention and post-intervention time points; in experimental studies, this reduction reached two standard deviations. Similar results (g = 1.21) were also found in another meta-analysis that evaluated the effectiveness of ICBT in children and adolescents. Even so, our results should be interpreted with caution, especially considering the small number of RCTs and the fact that all NRCTs were classified as having a high risk of bias in at least one of the topics analyzed, especially in confounding bias due to previous experience with CBT and medication use. In this sense, it is not possible to ensure that the effects observed in the meta-analysis of NRCTs are exclusively due to the GCBT interventions.

In addition, most of the protocols (n=6) included in this review were tested by only one study. This small number of RCTs and NRCTs assessing the effectiveness of CBT in adolescents with OCD was also reported by another meta-analysis that evaluated the effectiveness of CBT interventions in children and adolescents. Even so, our results should be interpreted with caution, especially considering the small number of RCTs and the fact that all NRCTs were classified as having a high risk of bias in at least one of the topics analyzed, especially in confounding bias due to previous experience with CBT and medication use. In this sense, it is not possible to ensure that the effects observed in the meta-analysis of NRCTs are exclusively due to the GCBT interventions.

In this sense, some studies indicate the influence of medication use (i.e., dosage and time of use) by part of the sample and/or previous experience with individual CBT or other psychotherapies on the results of GCBT interventions – especially considering that even individuals who do not respond well to individual CBT may experience some symptomatic improvement of OCD or comorbidities. In addition, some authors suggest that, compared to GCBT (40.9%), individual CBT yields a higher recovery rate (68.75%) in adults treated for OCD, and this rate remains higher in individual CBT (62.5%) even 1 year after the interventions. On the other hand, meta-analyses suggest that there is no significant difference in the effectiveness of individual CBT compared to GCBT in adult samples, with greater use of GCBT being recommended, as this modality can reduce waitlisting in health services.

Thus, there is a need for additional studies that investigate the effectiveness of GCBT in the treatment of adolescents with OCD considering the possibility of differences in the effect size that may be associated with the use of different intervention protocols or structures. In addition, the need for greater control of possible intervening variables (e.g., previous experience with individual CBT and/or use of medication) must be emphasized.

No conclusive evidence was identified considering the influence of a greater or lesser number of sessions (e.g., 7 or 14 sessions) or the duration of each session.
The effect size of the protocols that provided for seven sessions lasting 90 minutes was similar to the effects of studies that followed protocols that recommended 14 sessions lasting 90 minutes and 120 minutes. This finding is corroborated by other systematic reviews, which also found no evidence to support that the number or duration of sessions is associated with the effect size of the interventions. In any case, the hypothesis that increasing the number or duration of sessions will not result in greater efficacy in treatments with GCBT in adolescents with OCD must be confirmed by new RCTs.

The main limitations of this systematic review and meta-analysis concern the fact that only five databases were searched. Although these are the main databases in the field, other relevant studies may have been indexed in other databases. Another limitation concerns our absence of subgroup analyses (e.g., comparison between the effects of other interventions and GCBT) as proposed in the PROSPERO protocol. Such analyses were not performed since the included studies used different types of interventions that were not repeated between the studies and/or did not present enough data for inclusion in the meta-analysis (i.e., mean and standard deviation of the groups). In addition, most of the studies found were NRCTs with a sample allocated to a single pre- and post-test comparison group. Therefore, more RCTs that assess the effectiveness of GCBT compared to ICBT and control groups are recommended.

Finally, regardless of the country of origin of the seven intervention protocols located in our review, all were written in English. Considering the small number of protocols and their publication in a single language, the development and/or cross-cultural adaptation of protocols for the treatment of adolescents with OCD from other cultures/nationalities is recommended.

Acknowledgements

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; finance code 001) and by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

Disclosure

The authors report no conflicts of interest.

References

1 Associação Americana de Psiquiatria. Manual Diagnóstico e Estatístico de Transtornos Mentais, 5ª edição (DSM-5). Porto Alegre: Artmed; 2014.
2 Murray CJ, Lopez AD, World Health Organization (WHO), World Bank, Harvard School of Public Health. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary. WHO: Harvard University Press; 1996.
3 Ferrao YA, Shavitt RG, Bedin NR, de Mathis ME, Lopes AC, Fontenelle LF, et al. Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord. 2006;94:199-209.
4 Mathes BM, Morabito DM, Schmidt NB. Epidemiological and clinical gender differences in OCD. Curr Psychiatry Rep. 2019;21:35.

5 Brakoulias V, Starcevic V, Belloch A, Brown C, Fernao YA, Fontenelle LF, et al. Comorbidity, age of onset and suicidality in obsessive-compulsive disorder (OCD): an international collaboration. Compr Psychiatry. 2017;76:79-86.

6 Hollander E, Simeon D. Transtornos de ansiedade. In: Hales RE, Yudofsky SC, Babcock GO. Tratado de psiquiatria clinica. 5th ed. Porto Alegre: Artmed; 2012. p. 531-838.

7 Vivian AS, Rodrigues L, Wendt G, Bicca MG, Braga DT, Cordioli AV. Obsessive-compulsive symptoms and obsessive-compulsive disorder in adolescents: a population-based study. Braz J Psychiatry. 2014;36:111-8.

8 Pauls DL, Abravanel A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci. 2014;15:410-24.

9 Bozorgmehr A, Ghadivarsi M, Shahsavand AE. Obsessive-compulsive disorder, which genes? Which functions? Which pathways? An integrated holistic view regarding OCD and its complex genetic etiology. J Neurogenet. 2017;31:153-60.

10 Niu Q, Yang L, Song X, Chu C, Liu H, Zhang L, et al. Abnormal resting-state brain activities in patients with first-episode obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2017;13:507-13.

11 Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158:1568-78.

12 Purty A, Nestadt G, Samuels JF, Viswanath B. Genetics of obsessive-compulsive disorder. Indian J Psychiatry. 2019;61:S37-S42.

13 Barrett P, Farrell L, Dadds M, Boulter N. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: long-term follow-up and predictors of outcome. J Am Acad Child Adolesc Psychiatry. 2005;44:1005-14.

14 O'Leary EM, Barrett P, Fjermedstad KW. Cognitive-behavioral family treatment for childhood obsessive-compulsive disorder: a 7-year follow-up study. J Anxiety Disord. 2009;23:973-8.

15 Melin K, Skarphefðinsson G, Thomsen PH, Weidie B, Torp NC, Valderhaug R, et al. Treatment gains are sustainable in pediatric obsessive-compulsive disorder: three-year follow-up from the NordLOTS. J Am Acad Child Adolesc Psychiatry. 2020;59:244-53.

16 Fireman B, Koran LM, Leventhal JL, Jacobson A. The prevalence of obsessive-compulsive disorder, which genes? Which functions? Which pathways? An integrated holistic view regarding OCD and its complex genetic etiology. J Neurogenet. 2017;31:153-60.

17 Stengler-Wenzke K, Trosbach J, Dietrich S, Angermeyer MC. Experience of stigmatization by relatives of patients with obsessive-compulsive disorder. Psychiatr Nurs. 2004;18:88-96.

18 Monzani B, Vidal-Ribas P, Turner C, Krebs G, Stokes C, Heyman I, et al. The role of paternal accommodation of pediatric OCD symptoms: patterns and implications for treatment outcomes. J Abnorm Child Psychol. 2020;48:1313-23.

19 Raffin AL, Ferra˜o YA, Souza FP, Cordioli AV. Fatores preditores de

20 Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292:1969-76.

21 Correll CU, Cortese S, Croatto G, Monaco F, Kiniitis D, Arrondo G, et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry. 2021;20:24-75.

22 Asbahr FR, Castillo AR, Ito LM, Latorre MR, Moreira MN, Lotufo-Neto F. Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder. J Abnorm Child Psychol. 2005;33:419-31.

23 Torp NC, Dahl K, Skarphefðinsson G, Thomsen PH, Valderhaug R, Weidie B, et al. Effectiveness of cognitive behavior treatment for pediatric obsessive-compulsive disorder: acute outcomes from the Nordic Long-term OCD Treatment Study (NordLOTS). Behav Res Ther. 2015;64:15-23.

24 Przezeres AM, de Souza WF, Fontenelle LF. [Cognitive-behavior therapy for obsessive-compulsive disorder: a systematic review of the last decade]. Braz J Psychiatry. 2007;29:562-70.

25 Benazon NR, Ager J, Rosenberg DR. Cognitive behavior therapy in treatment-naive children and adolescent with obsessive compulsive disorder: an open trial. Behav Res Ther. 2002;40:529-39.

26 Geller DA, March J. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:98-113.

27 Mancuso E, Faro A, Joshi G, Geller DA. Treatment of pediatric obsessive-compulsive disorder: a review. J Child Adolesc Psycho-pharmacol. 2010;20:299-308.

28 Fischer DJ, Himle JA, Hanna GL. Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes. Res Soc Work Pract. 1998;8:629-96.

29 Thiennemann M, Martin J, Cregger B, Thompson HB, Dyer-Friedman J. Manual-driven group cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40:1254-60.

30 Barrett P, Healy-Farrell L, March J. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry. 2004;43:46-62.

31 Schubert DA, Selles RR, Stewart SE. Coercive and disruptive behaviors mediate group cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. Compr Psychiatry. 2018;86:74-81.

32 Belotto-Silva C, Diniz JB, Malavazzi DM, Valério C, Fossaçuva lu, Borcato S, et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Distord. 2012;26:25-31.

33 Mancuso E, Faro A, Joshi G, Geller DA. Treatment of pediatric obsessive-compulsive disorder: a review. J Child Adolesc Psycho-pharmacol. 2010;20:299-308.

34 Sun M, Rith-Najarian LR, Williamson TJ, Chorpita BF. Treatment features associated with youth cognitive behavioral therapy follow-up effects for internalizing disorders: a meta-analysis. J Clin Child Adolesc Psychol. 2019;48:S269-83.

35 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

36 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan – a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

37 Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-11.

38 Scabill H, Riddle MA, McSwiggin-Hardin M, Orł S, King RA, Goodman WK, et al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36:844-52.

39 Novara C, Pardini S, Cardona F, Pastore M. Comparing models of the Children Yale-Brown Obsessive Compulsive Scale (CY-BOCS) in an Italian clinical sample. Front Psychiatry. 2020;11:615.

40 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley and Sons. 2011.

41 Sterne JA, Hernán MA, McAleenan A, Reeves BC, Higgins JP. Assessing risk of bias in a non-randomized study. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Matthew J. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chapter 25. Hoboken: John Wiley & Sons; 2019. p. 621-41.

42 Schwarzer G. General package for meta-analysis [Internet]. 2021 Dec 3 [cited 2021 Mar 24]. cran.r-project.org/web/packages/meta/meta.pdf

43 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.

44 Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum Associates; 1988.

45 Krone KP, Himle JA, Nesse RM. A standardized behavioral group treatment program for obsessive-compulsive disorder: preliminary results. Behav Res Ther. 1991;29(6):627-31.

46 March JS, Mulle K. OCD in children and adolescents: A cognitive-behavioral treatment manual. Guilford Press; 1998.

Efficacy of GCBT in adolescents with OCD
47 Himle JA, Fischer DJ, Van Etten ML, Janeck AS, Hanna GL. Group behavioral therapy for adolescents with tic-related and non-tic-related obsessive-compulsive disorder. Depress Anxiety. 2003;17:73-7.

48 Fischer DJ, Himle JA, Hanna GL. “Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes.” Res Soc Work Pract. 1998;8(6):629-636.

49 Martin JL, Thiemann M. Group cognitive-behavior therapy with family involvement for middle-school-age children with obsessive-compulsive disorder: a pilot study. Child Psychiatry Hum Dev. 2005;36:113-27.

50 Farrell L, Waters A, Milliner E, Ollendick T. Comorbidity and treatment response in pediatric obsessive-compulsive disorder: a pilot study of group cognitive-behavioral treatment. Psychiatry Res. 2012;199:115-23.

51 Lavell CH, Farrell LJ, Waters AM, Cadman J. Predictors of treatment response to group cognitive behavioural therapy for pediatric obsessive-compulsive disorder. Psychiatry Res. 2016;245:186-93.

52 Fatori D, Pereira CA, Asbahr FR, Requena G, Alvarenga PG, de Mathis MA, et al. Adaptive treatment strategies for children and adolescents with obsessive-compulsive disorder: a sequential multiple assignment randomized trial. J Anxiety Disord. 2018;58:42-50.

53 Cordioli AV. TOC Vencendo o transtorno obsessivo-compulsivo Manual da terapia cognitivo-comportamental para pacientes e terapeutas. 2a ed. Porto Alegre: Artmed; 2008.

54 Selles RR, Heijgaard DR, Ivarsson T, Thomsen PH, McBride N, Storch EA, et al. Symptom insight in pediatric obsessive-compulsive disorder: outcomes of an international aggregated cross-sectional sample. J Am Acad Child Adolesc Psychiatry. 2018;57:615-9.e5.

55 Shabani MJ, Mohsenabadi H, Omidi A, Lee EB, Twohig MP, Ahmadvand A, et al. An Iranian study of group acceptance and commitment therapy versus group cognitive behavioral therapy for adolescents with obsessive-compulsive disorder on an optimal dose of selective serotonin reuptake inhibitors. J Obsessive Compuls Relat Disord. 2019;22:100440.

56 Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34:215-20.

57 Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol. 1976;104:493-8.

58 McGuire JF, Piacentini J, Lewin AB, Brennan EA, Murphy TK, Storch EA. A meta-analysis of cognitive behavior therapy and medication for child obsessive-compulsive disorder: moderators of treatment efficacy, response, and remission. Depress Anxiety. 2015;32:580-93.

59 Pozza A, Dettore D. Drop-out and efficacy of group versus individual cognitive behavioural therapy: what works best for obsessive-compulsive disorder? A systematic review and meta-analysis of direct comparisons. Psychiatry Res. 2017;258:24-36.

60 Cabedo E, Belloch A, Carrió C, Larsson C, Fernández-Alvarez H, García F. Group versus individual cognitive treatment for obsessive-compulsive disorder: changes in severity at post-treatment and one-year follow-up. Behav Cogn Psychother. 2010;38:227-32.

61 Schwartz D, Barkowski S, Burlingame GM, Strauss B, Rosendahl J. Efficacy of group psychotherapy for obsessive-compulsive disorder: a meta-analysis of randomized controlled trials. J Obsessive Compuls Relat Disord. 2016;10:49-61.

62 Turner C, O’Gorman B, Nair A, O’Kearney R. Moderators and predictors of response to cognitive behaviour therapy for pediatric obsessive-compulsive disorder: a systematic review. Psychiatry Res. 2018;261:50-60.